The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ramucirumab for patients with advanced hepatocellular carcinoma and elevated α-fetoprotein following a non-sorafenib based first-line therapy: Final results from an expansion cohort of REACH-2.
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CStone Pharmaceuticals; Eisai; Exelixis; Genentech/Roche; Lilly; Merck; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Expert Testimony - Bayer
 
Thomas Yau
Honoraria - AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology
Consulting or Advisory Role - Bristol-Myers Squibb
 
Chih-Hung Hsu
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Ono Pharmaceutical; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; MSD; Ono Pharmaceutical; Roche/Genentech
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Johnson & Johnson (Inst); Merck Serono (Inst); MSD (Inst); Nucana (Inst); Ono Pharmaceutical (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Ono Pharmaceutical; Roche/Genentech
 
Enrico N. De Toni
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Lilly; Pfizer; Roche; TERUMO
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Lilly; Pfizer; Roche; TERUMO
Research Funding - AstraZeneca; Bayer; Bristol-Myer Squibb; Ipsen; Lilly; Roche
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Bristol-Myers Squibb; Celsion; Roche
 
Lipika Goyal
Consulting or Advisory Role - Agios; Alentis Therapeutics; AstraZeneca; Debiopharm Group; Exelixis; Genentech; H3 Biomedicine; Incyte; Klus Pharma; QED Therapeutics; Sirtex Medical; Taiho Pharmaceutical
(OPTIONAL) Uncompensated Relationships - Agios; Debiopharm Group; Merck; Taiho Pharmaceutical
 
Peter R. Galle
Honoraria - Adaptimmune; AstraZeneca/MedImmune; Bayer Schering Pharma; Boston Scientific; Bristol-Myers Squibb; Guerbet; Ipsen; Lilly; MSD; Roche/Genentech; Sirtex Medical
Consulting or Advisory Role - Adaptimmune; Bayer Schering Pharma; Boston Scientific; Bristol-Myers Squibb; Lilly; MSD; Roche/Genentech; Sirtex Medical
Speakers' Bureau - Bayer Schering Pharma; Ipsen; Lilly; Roche
Research Funding - Roche/Genentech
Travel, Accommodations, Expenses - Bayer Schering Pharma; Lilly; Sirtex Medical
 
Shukui Qin
No Relationships to Disclose
 
Sujata Rao
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Travel, Accommodations, Expenses - Lilly
 
Fangfang Sun
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Chunxiao Wang
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Ryan C Widau
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Andrew X. Zhu
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; Exelixis; Gilead Sciences; Gilead Sciences; Lilly; Merck; Roche/Genentech; Sanofi/Aventis
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)